OBR Daily Commentary

forumImage

Studies Back Salvage RT After Prostatectomy

(MedPage Today) Sept 28, 2020 - Three randomized trials and a meta-analysis of the trials failed to show a significant effect on biochemical progression or combined clinical events after radical prostatectomy for early, high-risk prostate cancer.

Read Article arrow

Howard Sandler, MD, MS, FASTRO (Posted: September 29, 2020)

quotes

Multiple randomized trials comparing adjuvant RT after radical prostatectomy (with undetectable PSA) vs. early salvage (when the PSA becomes detectable). The PIs of each study agreed in advance to combine data in a meta-analysis. So far, it looks like early salvage is acceptable although the largest study, RADICALS, has not presented the primary endpoint of the study. As the editorial notes, the patients were pretty low risk. For high risk patients, adjuvant RT should still be considered -- many patients have a predicted risk of failure of >50%. Observing them is probably not ideal.

quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...